Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)

• Main Authors: Haruka Maeda (Author), Nobuo Saito (Author), Ataru Igarashi (Author), Masayuki Ishida (Author), Mayumi Terada (Author), Takayasu Ito (Author), Hideko Ikeda (Author), Hiroshi Kamura (Author), Iori Motohashi (Author), Yuya Kimura (Author), Masaru Komino (Author), Hiromi Arai (Author), Osamu Kuwamitsu (Author), Nobuhiro Akuzawa (Author), Eiichiro Sando (Author), Toru Morikawa (Author), Haruki Imura (Author), Hiroki Inoue (Author), Tomoichiro Hayakawa (Author), Osamu Teshigahara (Author), Yasuji Ohara (Author), Motoi Suzuki (Author), Konosuke Morimoto (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan. Methods We conducted a multicenter test-negative case-control study. The study comprised in...